NZ599949A - Drug combination with theobromine and its use in therapy - Google Patents
Drug combination with theobromine and its use in therapyInfo
- Publication number
- NZ599949A NZ599949A NZ599949A NZ59994910A NZ599949A NZ 599949 A NZ599949 A NZ 599949A NZ 599949 A NZ599949 A NZ 599949A NZ 59994910 A NZ59994910 A NZ 59994910A NZ 599949 A NZ599949 A NZ 599949A
- Authority
- NZ
- New Zealand
- Prior art keywords
- therapy
- theobromine
- drug combination
- opiate antitussive
- meprotixol
- Prior art date
Links
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 title abstract 4
- 238000002560 therapeutic procedure Methods 0.000 title abstract 3
- 229960004559 theobromine Drugs 0.000 title abstract 2
- 239000000890 drug combination Substances 0.000 title 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
- 230000000954 anitussive effect Effects 0.000 abstract 2
- 229940124584 antitussives Drugs 0.000 abstract 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 abstract 2
- 230000000631 nonopiate Effects 0.000 abstract 2
- JTUQXGZRVLWBCR-UHFFFAOYSA-N 1-[1-[2-(phenylmethyl)phenoxy]propan-2-yl]piperidine Chemical compound C1CCCCN1C(C)COC1=CC=CC=C1CC1=CC=CC=C1 JTUQXGZRVLWBCR-UHFFFAOYSA-N 0.000 abstract 1
- FLNXBVJLPJNOSI-UHFFFAOYSA-N 1-[2-[(4-chlorophenyl)-phenylmethoxy]ethyl]piperidine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 FLNXBVJLPJNOSI-UHFFFAOYSA-N 0.000 abstract 1
- CFJMRBQWBDQYMK-UHFFFAOYSA-N 1-phenyl-1-cyclopentanecarboxylic acid 2-[2-(diethylamino)ethoxy]ethyl ester Chemical compound C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 CFJMRBQWBDQYMK-UHFFFAOYSA-N 0.000 abstract 1
- PTVWPYVOOKLBCG-UHFFFAOYSA-N 3-(4-phenyl-1-piperazinyl)propane-1,2-diol Chemical compound C1CN(CC(O)CO)CCN1C1=CC=CC=C1 PTVWPYVOOKLBCG-UHFFFAOYSA-N 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 abstract 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 abstract 1
- IDCHQQSVJAAUQQ-UHFFFAOYSA-N N,N-diethyl-2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethanamine Chemical compound O1C(CCN(CC)CC)=NC(C=2C=CC=CC=2)=N1 IDCHQQSVJAAUQQ-UHFFFAOYSA-N 0.000 abstract 1
- RGEVWUKXWFOAID-UHFFFAOYSA-N Piperidione Chemical compound CCC1(CC)C(=O)CCNC1=O RGEVWUKXWFOAID-UHFFFAOYSA-N 0.000 abstract 1
- 229960001871 benproperine Drugs 0.000 abstract 1
- -1 benzonate Chemical compound 0.000 abstract 1
- 229950003903 bibenzonium Drugs 0.000 abstract 1
- LBRNZQRZDLLIHL-UHFFFAOYSA-N bibenzonium Chemical compound C=1C=CC=CC=1C(OCC[N+](C)(C)C)CC1=CC=CC=C1 LBRNZQRZDLLIHL-UHFFFAOYSA-N 0.000 abstract 1
- 229960004902 butamirate Drugs 0.000 abstract 1
- DDVUMDPCZWBYRA-UHFFFAOYSA-N butamirate Chemical compound CCN(CC)CCOCCOC(=O)C(CC)C1=CC=CC=C1 DDVUMDPCZWBYRA-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960004472 clofedanol Drugs 0.000 abstract 1
- WRCHFMBCVFFYEQ-UHFFFAOYSA-N clofedanol Chemical compound C=1C=CC=C(Cl)C=1C(O)(CCN(C)C)C1=CC=CC=C1 WRCHFMBCVFFYEQ-UHFFFAOYSA-N 0.000 abstract 1
- 229960002544 cloperastine Drugs 0.000 abstract 1
- 229960001985 dextromethorphan Drugs 0.000 abstract 1
- 229960000295 dibunate Drugs 0.000 abstract 1
- WBEBQCINXJDZCX-UHFFFAOYSA-N dibunic acid Chemical compound OS(=O)(=O)C1=C(C(C)(C)C)C=CC2=CC(C(C)(C)C)=CC=C21 WBEBQCINXJDZCX-UHFFFAOYSA-N 0.000 abstract 1
- 229960001056 dimemorfan Drugs 0.000 abstract 1
- KBEZZLAAKIIPFK-NJAFHUGGSA-N dimemorfan Chemical compound C1C2=CC=C(C)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 KBEZZLAAKIIPFK-NJAFHUGGSA-N 0.000 abstract 1
- 229960004722 dropropizine Drugs 0.000 abstract 1
- 229960004049 fedrilate Drugs 0.000 abstract 1
- RDEOYUSTRWNWLX-UHFFFAOYSA-N fedrilate Chemical compound C1COCCC1(C=1C=CC=CC=1)C(=O)OC(C)CCN1CCOCC1 RDEOYUSTRWNWLX-UHFFFAOYSA-N 0.000 abstract 1
- 229950008308 indantadol Drugs 0.000 abstract 1
- MNLULKBKWKTZPE-UHFFFAOYSA-N indantadol Chemical compound C1=CC=C2CC(NCC(=O)N)CC2=C1 MNLULKBKWKTZPE-UHFFFAOYSA-N 0.000 abstract 1
- 229960004216 isoaminile Drugs 0.000 abstract 1
- WFLSCFISQHLEED-UHFFFAOYSA-N isoaminile Chemical compound CN(C)C(C)CC(C(C)C)(C#N)C1=CC=CC=C1 WFLSCFISQHLEED-UHFFFAOYSA-N 0.000 abstract 1
- 229960002732 meprotixol Drugs 0.000 abstract 1
- LAYVFLWAVIGDLK-UHFFFAOYSA-N meprotixol Chemical compound C1=CC=C2C(O)(CCCN(C)C)C3=CC(OC)=CC=C3SC2=C1 LAYVFLWAVIGDLK-UHFFFAOYSA-N 0.000 abstract 1
- 229960001244 morclofone Drugs 0.000 abstract 1
- KVCJCEKJKGLBOK-UHFFFAOYSA-N morclofone Chemical compound COC1=CC(C(=O)C=2C=CC(Cl)=CC=2)=CC(OC)=C1OCCN1CCOCC1 KVCJCEKJKGLBOK-UHFFFAOYSA-N 0.000 abstract 1
- 229960003427 nepinalone Drugs 0.000 abstract 1
- RVXGRCNWGOHSDE-UHFFFAOYSA-N nepinalone Chemical compound O=C1CCC2=CC=CC=C2C1(C)CCN1CCCCC1 RVXGRCNWGOHSDE-UHFFFAOYSA-N 0.000 abstract 1
- 229960001754 oxeladin Drugs 0.000 abstract 1
- IQADUMSPOQKAAO-UHFFFAOYSA-N oxeladin Chemical compound CCN(CC)CCOCCOC(=O)C(CC)(CC)C1=CC=CC=C1 IQADUMSPOQKAAO-UHFFFAOYSA-N 0.000 abstract 1
- 229960003625 oxolamine Drugs 0.000 abstract 1
- 229960003436 pentoxyverine Drugs 0.000 abstract 1
- 229960003810 piperidione Drugs 0.000 abstract 1
- 229960004202 prenoxdiazine Drugs 0.000 abstract 1
- PXZDWASDNFWKSD-UHFFFAOYSA-N prenoxdiazine Chemical compound C1CCCCN1CCC(ON=1)=NC=1CC(C=1C=CC=CC=1)C1=CC=CC=C1 PXZDWASDNFWKSD-UHFFFAOYSA-N 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 229960000568 zipeprol Drugs 0.000 abstract 1
- VSTNNAYSCJQCQI-UHFFFAOYSA-N zipeprol Chemical compound C=1C=CC=CC=1C(OC)CN(CC1)CCN1CC(O)C(OC)C1=CC=CC=C1 VSTNNAYSCJQCQI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0919889.6A GB0919889D0 (en) | 2009-11-13 | 2009-11-13 | Drug composition and its use in therapy |
| PCT/GB2010/051895 WO2011058373A2 (en) | 2009-11-13 | 2010-11-12 | Drug combination with theobromine and its use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ599949A true NZ599949A (en) | 2013-08-30 |
Family
ID=41509324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ599949A NZ599949A (en) | 2009-11-13 | 2010-11-12 | Drug combination with theobromine and its use in therapy |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP2498777A2 (enExample) |
| JP (2) | JP2013510841A (enExample) |
| CN (1) | CN102753174A (enExample) |
| AU (1) | AU2010317667B2 (enExample) |
| BR (1) | BR112012011227A2 (enExample) |
| CA (1) | CA2780703A1 (enExample) |
| CO (1) | CO6551744A2 (enExample) |
| GB (1) | GB0919889D0 (enExample) |
| IL (1) | IL219768A0 (enExample) |
| MX (1) | MX2012005532A (enExample) |
| NZ (1) | NZ599949A (enExample) |
| PE (1) | PE20130147A1 (enExample) |
| PH (1) | PH12012501369A1 (enExample) |
| RU (1) | RU2519086C2 (enExample) |
| UA (1) | UA108993C2 (enExample) |
| WO (1) | WO2011058373A2 (enExample) |
| ZA (1) | ZA201204248B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10016437B2 (en) | 2009-06-16 | 2018-07-10 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| GB201111485D0 (en) * | 2011-07-05 | 2011-08-17 | Biocopea Ltd | Drug composition and its use in therapy |
| US9308211B2 (en) | 2009-06-16 | 2016-04-12 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| US9314465B2 (en) | 2009-06-16 | 2016-04-19 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| GB0910375D0 (en) | 2009-06-16 | 2009-07-29 | Biocopea Ltd | Drug composition and its use in therapy |
| WO2017117347A1 (en) * | 2015-12-30 | 2017-07-06 | Markovitz M D Paul | Method of treating schizophrenia |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834479A (en) * | 1993-03-05 | 1998-11-10 | Mayer; David J. | Method and composition for alleviating pain |
| CA2272640C (en) * | 1996-11-25 | 2003-07-08 | The Procter & Gamble Company | Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists |
| HUP9700654A2 (hu) * | 1997-03-26 | 1999-09-28 | Dezső Korbonits | Teobromin tartalmú köhögéscsillapító készítmények |
| US20030206942A1 (en) * | 1998-09-25 | 2003-11-06 | Neema Kulkarni | Fast dissolving orally consumable films containing an antitussive and a mucosa coating agent |
| US6207674B1 (en) * | 1999-12-22 | 2001-03-27 | Richard A. Smith | Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants |
| WO2004105705A1 (en) * | 2003-05-29 | 2004-12-09 | Unilever Plc | Hair treatment compositions |
| US20060153926A1 (en) * | 2005-01-10 | 2006-07-13 | Bascom Charles C | Compositions, products and methods for controlling weight in a mammal |
| US20080003280A1 (en) * | 2006-06-26 | 2008-01-03 | Levine Brian M | Combination cough treatment compounds and method of treating common coughs |
| US20080176955A1 (en) * | 2007-01-16 | 2008-07-24 | Victory Pharma, Inc. | Combined administration of benzonatate and guaifenesin |
-
2009
- 2009-11-13 GB GBGB0919889.6A patent/GB0919889D0/en not_active Ceased
-
2010
- 2010-11-12 EP EP10825831A patent/EP2498777A2/en not_active Ceased
- 2010-11-12 NZ NZ599949A patent/NZ599949A/xx not_active IP Right Cessation
- 2010-11-12 CN CN2010800516299A patent/CN102753174A/zh active Pending
- 2010-11-12 WO PCT/GB2010/051895 patent/WO2011058373A2/en not_active Ceased
- 2010-11-12 PE PE2012000649A patent/PE20130147A1/es not_active Application Discontinuation
- 2010-11-12 PH PH1/2012/501369A patent/PH12012501369A1/en unknown
- 2010-11-12 AU AU2010317667A patent/AU2010317667B2/en not_active Ceased
- 2010-11-12 JP JP2012538415A patent/JP2013510841A/ja active Pending
- 2010-11-12 MX MX2012005532A patent/MX2012005532A/es active IP Right Grant
- 2010-11-12 BR BR112012011227A patent/BR112012011227A2/pt not_active IP Right Cessation
- 2010-11-12 CA CA2780703A patent/CA2780703A1/en not_active Abandoned
- 2010-11-12 RU RU2012124038/15A patent/RU2519086C2/ru not_active IP Right Cessation
- 2010-12-11 UA UAA201207164A patent/UA108993C2/en unknown
-
2012
- 2012-05-11 CO CO12078027A patent/CO6551744A2/es not_active Application Discontinuation
- 2012-05-13 IL IL219768A patent/IL219768A0/en unknown
- 2012-06-11 ZA ZA2012/04248A patent/ZA201204248B/en unknown
-
2016
- 2016-01-07 JP JP2016001487A patent/JP6118919B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013510841A (ja) | 2013-03-28 |
| CA2780703A1 (en) | 2011-05-19 |
| RU2519086C2 (ru) | 2014-06-10 |
| JP2016128439A (ja) | 2016-07-14 |
| CO6551744A2 (es) | 2012-10-31 |
| EP2498777A2 (en) | 2012-09-19 |
| GB0919889D0 (en) | 2009-12-30 |
| ZA201204248B (en) | 2013-02-27 |
| WO2011058373A2 (en) | 2011-05-19 |
| PE20130147A1 (es) | 2013-03-13 |
| BR112012011227A2 (pt) | 2017-06-13 |
| IL219768A0 (en) | 2012-07-31 |
| WO2011058373A3 (en) | 2011-07-07 |
| RU2012124038A (ru) | 2013-12-20 |
| UA108993C2 (en) | 2015-07-10 |
| AU2010317667B2 (en) | 2014-05-29 |
| CN102753174A (zh) | 2012-10-24 |
| JP6118919B2 (ja) | 2017-04-19 |
| MX2012005532A (es) | 2012-09-28 |
| PH12012501369A1 (en) | 2012-10-22 |
| AU2010317667A1 (en) | 2012-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ599949A (en) | Drug combination with theobromine and its use in therapy | |
| WO2007053698A3 (en) | Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms | |
| Monteiro et al. | Effects of methadone, alone or in combination with acepromazine or xylazine, on sedation and physiologic values in dogs | |
| AU2012280019B2 (en) | Drug combinations and uses in treating a coughing condition | |
| AU2003235838A1 (en) | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor | |
| EA200800168A1 (ru) | Гидрохлориды и гидраты 1-[(3-цианопиридин-2-ил)метил]-3-метил-7-(2-бутин-1-ил)-8-(3-аминопиперидин-1-ил)ксантина, их получение и их применение в качестве лекарственных средств | |
| AU2003275357A1 (en) | Analgesic compositions comprising nmda receptor antagonists and benzalkonium chloride | |
| NZ610921A (en) | A tamper resistant dosage form comprising melt extruded particulates in a matrix | |
| JP2004515455A5 (enExample) | ||
| HUP0102658A2 (hu) | Opioid agonista és opioid antagonista hatóanyag-kombinációt tartalmazó gyógyszerkészítmény | |
| HUP0401735A3 (en) | Piperazine derivatives with ccr1 receptor antagonist activity and pharmaceutical compositions containing them | |
| RU2000119778A (ru) | Комбинации агонист/антагонист опиоида | |
| RU2011121513A (ru) | Новые и эффективные лекарственные формы тапентадола | |
| NZ707213A (en) | Compositions and methods of treating pulmonary hypertension | |
| UA106225C2 (ru) | СОЛИ ПРОИЗВОДНЫХ ТЕТРАГИДРОИМИДАЗО[1,5-а]ПИРАЗИНА, СПОСОБ ПОЛУЧЕНИЯ (ВАРИАНТЫ) И ИХ МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ | |
| HUP0003194A2 (hu) | Triozin-kináz-gátló alkalmazása prosztatarák kezelésére szolgáló szinergista gyógyszerkészítményben | |
| WO2009076236A3 (en) | Micronized opioid compositions, formulations and dosage forms and methods of making same | |
| JP2014532078A5 (enExample) | ||
| WO2004022002A3 (en) | Combined immediate release and extended release analgesic composition | |
| JP2013510841A5 (enExample) | ||
| Boyle et al. | Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED | |
| IL178475A0 (en) | Sustained release formulation for oral administration of hmg-coa reductase inhibitor and method for the preparation thereof | |
| EP1849460A3 (en) | Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms | |
| RU2002123503A (ru) | Анальгезирующее, спазмолитическое, противовоспалительное лекарственное средство | |
| US9700561B2 (en) | Drug combinations and uses in treating a coughing condition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 NOV 2015 BY OLCOTT Effective date: 20141012 |
|
| ASS | Change of ownership |
Owner name: INFIRST HEALTHCARE LIMITED, GB Effective date: 20141106 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 NOV 2016 BY OLCOTT Effective date: 20151103 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 NOV 2017 BY 618575 Effective date: 20161102 |
|
| LAPS | Patent lapsed |